Search

everythinglearnresearchcommunity

for

Search:↓

New hair regrowth model introduced, imiquimod kills skin cancer cells, T-cadherin loss makes skin cancer more invasive, no strong link between PTCH1 gene and skin cancer after transplant, and male teens more likely to have hereditary hair loss.

Mutations in hKAP1 genes may cause hereditary hair disorders.

Injecting certain cells into mice caused hair loss, which was preventable with a specific inhibitor.

ETS2 drives cancer progression in squamous cell carcinoma and is linked to poor patient outcomes.

A new mutation linked to partial Androgen Insensitivity Syndrome and prostate cancer was found in a patient unhappy with their female gender assignment.

The mTOR signaling pathway might play a role in radiation dermatitis, but more research is needed.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

A new mutation in the AGPAT2 gene causes severe fat tissue loss and related health issues by reducing the protein's levels.

The tumor suppressor BRCA2 helps in cell division by bringing key proteins to the area where cells split.

The C-allele and CC-genotype in the PTPN22 gene lower the risk of alopecia areata.

New markers and pathways have been found in skin tumors, helping better understand and diagnose them.

JAK inhibitors may help improve symptoms in adults with APECED.

The A allele of the C2 gene increases the risk of lupus, while the G allele may protect against it.

Genetic analysis is crucial for diagnosing and managing cerebral arteriopathy.

High ornithine decarboxylase levels may lead to hair loss and cancer by increasing CK2 activity in the nucleus.

Genetic mutations linked to ectodermal dysplasias and hair loss were identified in Pakistani families.

A specific gene variant is linked to heart disease, increased heart muscle, curly hair, and thick skin on palms and soles.

A mutation in the KRT25 gene causes woolly hair and hair loss.

JAK inhibitors can enter the skin through hair follicles using a unique pathway.

New mutations in hair keratin genes can change hair structure and cause monilethrix, with nail issues more common in certain gene mutations.

Alopecia areata patients show unique protein activity patterns, suggesting imbalanced signaling pathways.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.

Higher TGF-β signaling may increase skin cancer risk in organ transplant recipients.

A specific hair protein variant increases the spread of breast cancer and is linked to worse survival rates.

The Bsk mutation doesn't involve keratin gene recombination and its cause is unknown.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Many patients on new leukemia drugs had mild to moderate skin reactions.

A mutation in the KRT74 gene causes woolly hair by affecting hair texture.

The S250C variant in a gene may cause autoimmunity and immunodeficiency by impairing protein function.